Phase 1
In 2014, Exelixis’ Cabometyx (cabozantinib) failed to show survival benefit as a monotherapy in prostate cancer.
Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.
Although CRISPR gene editing is touted as likely to revolutionize medicine, the actual proof of its effectiveness and safety in treating diseases has been slow in coming. At least until now. Sort of.
The immuno-oncology therapy, CAR-T, utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged, and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type of immune cell called Natural Killer (NK) cells.
Evotec SE announced that its partner Bayer AG has decided to advance a further programme from the endometriosis multi-target alliance into clinical Phase I development.
Pharma companies from across the globe provide updates on their pipelines and business.
Krystal Biotech and Foghorn Therapeutics are beginning 2020 with significant expansion projects.
There were plenty of clinical trial announcements this week. Here’s a look.
Companies from across the globe provide updates to their business and pipeline.
In 2016, Soon-Shiong announced the Cancer Moonshot and set a 2020 deadline, claiming he would transform the war on cancer.
PRESS RELEASES